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Abstract
The important role of the CD8+ T-cells on HIV control is well established. However, correlates of immune protection remain
elusive. Although the importance of CD8+ T-cell specificity and functionality in virus control has been underscored, further
unraveling the link between CD8+ T-cell differentiation and viral control is needed. Here, an immunophenotypic analysis (in
terms of memory markers and Programmed cell death 1 (PD-1) expression) of the CD8+ T-cell subset found in primary HIV
infection (PHI) was performed. The aim was to seek for associations with functional properties of the CD8+ T-cell subsets,
viral control and subsequent disease progression. Also, results were compared with samples from Chronics and Elite
Controllers. It was found that normal maturation of total and HIV-specific CD8+ T-cells into memory subsets is skewed in PHI,
but not at the dramatic level observed in Chronics. Within the HIV-specific compartment, this alteration was evidenced by
an accumulation of effector memory CD8+ T (TEM) cells over fully differentiated terminal effector CD8
+ T (TTE) cells.
Furthermore, higher proportions of total and HIV-specific CD8+ TEM cells and higher HIV-specific TEM/(TEM+TTE) ratio
correlated with markers of faster progression. Analysis of PD-1 expression on total and HIV-specific CD8+ T-cells from PHI
subjects revealed not only an association with disease progression but also with skewed memory CD8+ T-cell differentiation.
Most notably, significant direct correlations were obtained between the functional capacity of CD8+ T-cells to inhibit viral
replication in vitro with higher proportions of fully-differentiated HIV-specific CD8+ TTE cells, both at baseline and at 12
months post-infection. Thus, a relationship between preservation of CD8+ T-cell differentiation pathway and cell
functionality was established. This report presents evidence concerning the link among CD8+ T-cell function, phenotype and
virus control, hence supporting the instauration of early interventions to prevent irreversible immune damage.
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Introduction
Human Immunodeficiency Virus (HIV) infection causes an
irreversible deterioration of the immune system ultimately leading
to the development of AIDS in the vast majority of infected
persons. Following virus transmission, acute/early phase of
infection is characterized by high levels of peak viremia, rapid
loss of CD4+ T-cells in both peripheral blood and mucosal
lymphoid tissues, and in some cases clinical symptoms [1].
Emergence of HIV-specific CD8+ T-cell response is associated
with the drop of plasma viremia to a stable level; known as the
viral set point [2] [3]. Given the central role that HIV-specific
CD8+ T-cells play in the control of viral replication [4,5], special
emphasis has been focused on this cell population. In order to help
design an effective HIV vaccine, different parameters such as the
magnitude, specificity and functionality of the CD8 response were
extensively studied in different settings. Many of these works
asserted that the quality of the response, rather than the quantity,
might play an important role [6–10][11–15]. Also, the phenotype
of the CD8+ T-cell response is an important component of
effective anti-viral immunity. Moreover, phenotype and function
are two attributes of the response essentially linked and many
research lines are currently being directed at understanding which
populations along the CD8+ T-cell differentiation pathway are
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most effective in inhibiting viral replication. Recent works shed
light on the complex differentiation profiles of the total and HIV-
specific CD8+ memory T-cells and their association with antiviral
function and disease progression [16–19].
There exists a large amount of publications reporting the
characterization of HIV-specific CD8+ T-cells in chronic infection,
however works performed during the acute infection are more
limited [14,15]. Moreover, in both cases most reports were based
on subtype B or C infected cohorts rather than non-subtype B/C
cohorts [16]. Our group has previously studied multiple aspects of
the HIV-specific CD8+ T-cell subsets during acute/early HIV
infection. Our findings were the first to report the immunological
aspects and CD8 profile of an Argentinean cohort during the
acute/early infection [20,21]. Our last report showed that the
early relative immunodominance of Gag-specific cells was
associated with delayed disease progression. Also, these Gag-
specific CD8+ T-cells had a higher capacity to degranulate, secrete
IFN-c and mediate viral inhibition activity in vitro (VIA). The
main contribution of this study relied on the correlation between
HIV-specific CD8+ T-cell functional properties during acute/early
infection and clinical outcomes over the first year post-infection.
Here, we present novel results from our ongoing work on an
Argentinean cohort of recently infected subjects. As an extension
of our preceding works, we aimed at performing an immunophe-
notypic analysis (in terms of memory markers and Programmed
cell death 1 (PD-1) expression) of the CD8+ T-cell differentiation
profile found in primary infection with viral control and
subsequent disease progression. Additionally, associations between
HIV-specific CD8+ T cell phenotype and functional properties
(more specifically antiviral capacity) were studied. Evidence
supporting these notions is provided.
Materials and Methods
Study population
A total of 63 subjects participated in this study: 10 healthy HIV-
seronegative donors (HD) and 53 HIV-infected patients: 32 were
enrolled during primary HIV infection (PHI), 10 were chronically
infected (Chronics) and 11 were Elite Controllers (EC) (Table 1
and Table S1). PHI subjects were enrolled by the Grupo Argentino
de Seroconversio´n Study Group [22] under the following inclusion
criteria: (1) detection of HIV RNA or p24 antigen with a
simultaneous negative or indeterminate Western Blot assay; or (2)
positive Western Blot with a negative test within the previous six
months. Chronically infected patients were defined as subjects
with established HIV infection for over 3 years, detectable viral
load (VL, .50 HIV RNA copies/ml plasma) and HAART
(Highly Active Anti-Retroviral Therapy) naı¨ve, while EC were
defined as subjects infected for more than 5 years with
undetectable VL (,50 HIV RNA copies/ml plasma), CD4+ T-
cell counts .450 cells/ml blood, HAART naı¨ve and no record of
opportunistic infections and/or AIDS-related diseases. HD
samples were obtained from voluntary blood donors at the
Sanatorio Dr Julio Mendez blood bank (Buenos Aires, Argentina).
All donors were .18 years; completed and passed a survey on
blood donation; and were screened for serological markers before
being accepted as donors.
Human samples
Blood samples were collected from study participants at
enrollment, centrifuged to separate plasma, which was stored at
280uC until use. Peripheral blood mononuclear cells (PBMCs)
were isolated by Ficoll-Hypaque density gradient centrifugation
(GE Healthcare, Little Chalfont/Buckinghamshire, UK) and
cryopreserved for subsequent phenotypic and functional assays.
PBMC cryopreservation and thawing were performed following
protocols developed to obtain an optimal detection of antigen
specific T-cell responses [23–25]. For PHI subjects, samples were
obtained at enrollment (baseline) and at 3, 6, 9, and 12 months
post-infection. Samples used for immunophenotypic and function-
al analyses were obtained from subjects that remained HAART-
naı¨ve at the moment of sampling. In the case PHI subject needed
to start HAART early, baseline samples were obtained before
treatment instauration. Plasma VL (branched-DNA, Versant
HIV-1 RNA 3.0 assay; Siemens Healthcare, Sudbury/Suffolk,
UK) and CD4+ T-cell count (flow cytometry double platform, BD
FACSCanto; BD Biosciences, San Diego/California, USA) were
assessed in HIV-infected subjects.
Human Subject Research Ethic Statement
Blood samples from HIV-infected individuals and healthy
donors were obtained for this study. Prior to enrollment, the
study was reviewed and approved by two institutional review
boards (IRB): Comite´ de E´tica Humana, Facultad de Medicina,
Universidad de Buenos Aires and Comite´ de Bioe´tica, Fundacio´n
Hue´sped (Buenos Aires, Argentina). Both HIV-infected partici-
pants and healthy donors provided written informed consents
accepting to participate in this study.
Peptides
Potential T-cell epitope (PTE) peptide panels corresponding to
Nef, Gag and Env proteins and the CEF (cytomegalovirus -CMV- ,
Epstein-Barr virus, and influenza virus) peptide pool were obtained
from the NIH AIDS Reagent Program (NIH, Bethesda/Maryland,
USA) [26,27]. Lyophilized peptides were dissolved in dimethyl
sulfoxide (DMSO, Sigma-Aldrich, St Louis/Missouri, USA) at
40 mg/ml and stored at 220uC.
PTE peptides are 15 amino acids (a.a.) in length and contain
naturally-occurring 9 a.a. sequences that are potential T-cell
determinants embedded in the sequences of circulating HIV-1
strains worldwide. Here, PTE peptides were grouped in 9 pools:
1xNef (N = 127 peptides), 3xGag (corresponding to p17 (N = 97),
p24 (N = 128) and p2p7p1p6 (denoted as RG, N = 95), and 5xEnv
(Gp120A1 -N = 73, spans HXB2 Env a.a. positions 1–154-,
Gp120A2 -N = 73, 157–284-, Gp120B -N = 105, 287–511-,
Gp41A -N = 114, 513–689-, Gp41B -N = 115, 689–842-).
Phenotypic and functional analysis of CD8+ T-cells by
flow cytometry
T-cell phenotypic and functional markers were measured to
identify total and HIV-specific CD8+ T-cell memory populations
following the protocol published before [20,21] with the following
modifications: Cryopreserved PBMCs were thawed and rested
overnight in RPMI medium (Sigma-Aldrich, St Louis/Missouri,
USA) supplemented with 10% fetal bovine serum (Gibco, Grand
Island/NY, USA), 2 mM L-glutamine (Sigma-Aldrich, St Louis/
Missouri, USA), 100 U/ml penicillin (Sigma-Aldrich, St Louis/
Missouri, USA), 100 mg/ml streptomycin (Sigma-Aldrich, St
Louis/Missouri, USA), and 10 mM HEPES (Gibco, Grand
Island/NY, USA). Cell viability was checked both immediately
after thawing and after overnight rest by trypan blue exclusion.
Only samples with good cell recovery (.70%) and good viability
(.95%) both after thawing and resting, were used in the assays.
PBMCs were dispensed in U-bottom 96-well plates (56105 cells/
well) in duplicate wells. Costimulatory antibodies (anti-CD28 and
anti-CD49d antibodies (1 mg/ml; BD Biosciences, San Jose/
California, USA), monensin (Golgistop, 0.7 ml/ml; BD Bioscienc-
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es, San Jose/California, USA), brefeldin A (10 mg/ml; BD
Biosciences, San Jose/California, USA), and the corresponding
peptide pool (2 mg/ml) were added. Also, a mixture of anti-
CD107A-fluorescein isothiocyanate (FITC) and anti-CD107B-
FITC antibodies (BD Biosciences, San Jose/California, USA) was
added in each well. An unstimulated (peptide-free medium plus
0.5% DMSO and costimulatory antibodies) and two positive
controls (2 mg/ml CEF peptide pool and phorbol myristate acetate
(PMA)-ionomycin (Sigma-Aldrich, St Louis/Missouri, USA)) were
included in each assay. Cells were incubated for 5 hours at 37uC,
washed, and stained for 30 min at 37uC with anti-CCR7-
phycoerythrin (PE) (BD Biosciences, San Jose/California, USA),
followed by staining for 30 min at 4uC, with LIVE/DEAD Fixable
NEAR-IR (Invitrogen, Life Technologies, Carlsbad/California,
USA), in order to exclude dead cells, and anti-CD3, -CD8 and
-CD45RO antibodies conjugated to -PECy7, -APC and -PeCy5.5
(BD Biosciences, San Jose/California, USA) respectively. For PD-
1 analysis, stimulated PBMCs were surface stained with a separate
panel that included anti-PD-1-PE (BD Biosciences, San Jose/
California, USA), anti-CD3-PECy7, anti-CD8-APC and LIVE/
DEAD Fixable NEAR-IR. Then, cells were permeabilized and
fixed using the Cytofix/Cytoperm kit (BD Biosciences, San Jose/
California, USA), following the manufacturer’s protocol. After the
permeabilization/fixation step, cells were stained intracellularly
with anti-IL-2, anti-TNF-a, and anti-IFN-c antibodies, all of them
conjugated to FITC (BD Biosciences, San Jose/California, USA).
Cells were then washed, resuspended in 0.5% paraformaldehyde
(PFA, Merck & Co, Whitehouse station/New Jersey, USA) and
stored until data acquisition in a 2-laser, 6-color BD FACSCanto
flow cytometer. Data acquisition and analysis were performed
using the BD FACSDiva v 6.1.3 software (BD Biosciences, San
Jose/California, USA). FlowJo Vx.0.7 free trial software (FlowJo
Enterprise, Treestar Inc., Ashland/Oregon, USA) was used to
generate Figure 1A and Figure S1 only for illustration purposes.
Instrument settings and fluorescence compensation were per-
formed on each testing day using unstained and single-stained
samples. Isotype controls, consisting of stimulated cells stained
with anti-CD3 and anti-CD8 conjugated antibodies and isotype
controls corresponding to phenotype (CCR7, CD45RO and PD-
1) and intracellular markers, were performed for each patient in
order to accurately set negative populations. First, a plot of
forward scatter area (FSC-A) versus height (FSC-H) was
constructed to remove doublets. Then, gating was performed on
small lymphocytes in a FSC versus side scatter (SSC) plot. At least
80,000 events were acquired in the lymphocyte gate. Dead cells
were then excluded on the bases of LIVE/DEAD fluorescence.
Subsequently, CD3+ CD8+ cells were gated in a CD3-versus-CD8
dot plot. HIV-specific CD8+ T-cells were identified in a CD8 vs.
cytokines (FITC) density plot (the gating strategy is provided in
Figure S1). A positive cytokine response was defined as at least
twice background, .0.05% after subtraction of background, and
at least 50 events. This criterion was established to minimize the
possibility of error due to a low number of events when further
subdividing these cells into memory subsets. For phenotypic
analysis, CD45RO vs. CCR7 density plot or PD-1 histogram were
performed on gated CD8+ cells. Distribution of different
phenotype subsets were analyzed both in total and HIV-specific
CD8+ T-cell compartments.
Immune Activation
CD4+ and CD8+ lymphocyte activation was analyzed on
thawed and over-night rested PBMCs by flow cytometry. Cells
were stained for 30 min at 4uC with LIVE/DEAD Fixable
NEAR-IR in order to exclude dead cells, and with the following
fluorochrome-conjugated antibodies (all of them obtained from
BD Biosciences, San Jose/California, USA): anti-HLA-DR-FITC,
anti-CD4-PerCP, anti-CD38-APC, anti-CD3-PeCy7 and anti-
CD8-PE.
Data acquisition and analysis was performed using the BD
FACSDiva software. Initial gating was performed on living
lymphocytes followed by gating on CD3+CD4+ or CD3+CD8+
events. Isotype-matched FITC- and APC-conjugated non-specific
antibodies were used in each sample in order to accurately set
HLA-DR and CD38 negative populations.
CD8+ T-cell Virus Inhibitory Activity (VIA) and CD8+ T-cell
polyfuntionality
The ex vivo ability of CD8+ T-cell to inhibit viral replication in
primary autologous CD4+ T-cells (VIA) and the capacity of HIV-
specific CD8+ T-cells to produce cytokines (IL-2, IFN-c and TNF-
a) and degranulate (evidenced by CD107A/B mobilization) upon
stimulation as well as its polyfunctionality were evaluated exactly
as published elsewhere [20].
Table 1. Summary of clinical data corresponding to HIV+ subjects enrolled per study group.
Viral loada,c
Group (No. of
subjects)
Median Days
post-infection (IQ)
Median RNA
copies/ml (IQ)
Mean log10
± SD
Viral set pointd
(mean log10
± SD)
CD4+ T-cell
countb,c, median
No. of cells/ml (IQ)
CD4 set pointd,
median No. of
cells/ml (IQ)
PHI
All (n = 32) 60 (30–90) 34,800 (8,843–252,588) 4.660.9 4.560.7 503 (320–682) 517 (404–629)
PHI .350 (n = 20) 60 (49–113) 18,471 (6,010–98,650) 4.360.9 4.360.6 618 (510–771) 573 (454–652)
PHI ,350 (n = 12) 55 (30–90) 151,026 (34,510–500,000) 5.160.8 5.160.7 281 (230–338) 256 (158–319)
Chronic (n =10) - 28,435 (9,449–197,984) 4.560.7 141 (11–563)
EC (n=11) - ,50 ,1.7 602 (562–888)
aVersant HIV-1 RNA 3.0 assay, Siemens. Lower and upper detection limits are 50 and 500,000 RNA copies/ml, respectively (1.7 and 5.7log10).
bFlow cytometry double platform, FACSCanto, BD Biosciences.
cFor PHI subjects, data correspond to baseline samples. For chronic and elite controller subjects, data correspond to samples obtained at enrollment.
dSet points were not calculated for subjects that initiated HAART during the first year post-infection.
IQ: Interquartile range.
doi:10.1371/journal.pone.0104235.t001
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Quantification of soluble plasma factors
Simultaneous determination of the following 39 cytokines and
chemokines was performed in plasma samples from a subset of 18
PHI subjects (at baseline time-point only) using Luminex
technology (MILLIPLEX MAP Human Cytokine/Chemokine,
Merck Millipore, Billerica/Massachusetts, USA): EGF, Eotaxin,
FGF-2, Flt-3 Ligand, Fractalkine, G-CSF, GM-CSF, GRO, IFN-
a2, IFN-c, IL-1a, IL-1b, IL-1ra, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7,
IL-8, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17,
IP-10, MCP-1, MCP-3, MDC (CCL22), MIP-1a, MIP-1b,
sCD40L, sIL-2Ra, TGF-a, TNF-a, TNF-b, VEGF. Samples
were processed and analyzed as described by Giavedoni et al [28].
Figure 1. Distribution of memory sub-populations within bulk and HIV-specific CD8+ T-cells. (A) Density and overlay dot plots of memory
subsets in total (density) and HIV-specific CD8+ T-cells (colored dots) of one representative subject per study group. The four defined sub-populations
are identified within each quadrant: TN and TN-L = Naı¨ve and Naı¨ve-like T-cells, respectively (CCR7
+/CD45RO2); TCM = central memory T-cells (CCR7
+/
CD45RO+); TEM = effector memory T-cells (CCR7
2/CD45RO+); TTE = terminal effectors T-cells (CCR7
2/CD45RO2). Proportions of each memory subset of
total (in black) and HIV-specific (in color) CD8+ T-cells are also shown. Panels B and C: Percentage of bulk (B) and HIV-specific (C) CD8+ T-cells subsets
of subjects enrolled per study group. Primary HIV infection (PHI) N = 24 subjects (31 specific responses); Elite Controllers (EC) N = 11 subjects (16
specific responses); Chronics N = 10 subjects (13 specific responses); Healthy Donors (HD) N = 10. Horizontal lines stand for median values. P values
were calculated using Mann-Whitney test. Asterisks denote different P values: * P,0.05; ** P,0.005; *** P,0.001.
doi:10.1371/journal.pone.0104235.g001
CD8+ T-Cell Phenotype in Primary HIV Infection
PLOS ONE | www.plosone.org 4 August 2014 | Volume 9 | Issue 8 | e104235
Data analysis
For PHI subjects, presumed date of infection was calculated as
described in [22]. Viral and CD4+ T-cell set-points were
calculated as the geometric mean of the determinations obtained
between 6 and 12 months post-presumed date of infection. Set-
points were not calculated for those subjects who started HAART
during the first 12 months of infection or if no stable set-point was
reached during that period. Starting from pilot sample data, pre-
study estimations of final sample sizes were determined using
Harris, Horvitz, Mood method in order to provide 80% power, at
the 5% level of significance. Statistical analyses were performed
using GraphPad Prism 5 (GraphPad Software Inc., La Jolla/
California, USA). All data, except log10 VL, were analyzed using
nonparametric statistics. Two-tailed Wilcoxon and Mann-Whitney
tests were used to compare intra- and inter-group variables,
respectively. Correlations were determined using Spearman’s rank
test. All tests were considered significant if the p value obtained
was less than 0.05.
Results
Study subjects description
In order to accomplish the aims of this study, three groups of
HIV-infected subjects were enrolled: 32 subjects were recruited
during HIV seroconversion and/or within 6 months since the
presumed date of infection (PHI group), 10 chronically-infected
subjects (Chronics), and 11 subjects defined as Elite Controllers
(EC) according to the criteria defined in Materials and Methods.
Detailed description of the HIV infected participants is shown in
Table 1, Figure S2, and Table S1. Additionally, samples from 10
HIV-negative healthy donors (HD) were obtained. Baseline
sample for PHI subjects were obtained at a median of 60 days
post-presumed date of infection and most corresponded to Fiebig
stages V and VI [29]. As regards chronically infected subjects, the
individuals enrolled in this study include subjects with preserved
immune status as well as subjects with advanced immune
deterioration (as observed in Table S1 and Figure S2), providing
evidence of the natural heterogeneity of such HIV-positive
population. Additionally, immune activation was evaluated in all
groups of HIV-infected subjects as it is known to be a major
predictor of disease progression [30]. The percentages of CD4+
and CD8+ T-cells that expressed the immune activation markers
CD38 and HLA-DR, either alone or in combination, were
determined by flow cytometry. Results are shown in Figure S2C
and Table 2. As expected, highest levels of immune activation
were observed in baseline samples from PHIs, followed by
Chronics and ECs.
For certain analyses, PHI subjects were further divided into two
subgroups whether their CD4+ T-cell count dropped below 350
cells/ml at any time during the first year post-infection or not
(PHI,350 and PHI.350, respectively, Table S1). By doing so, we
aimed to differentiate subjects with more rapid or aggressive
progression of infection (PHI,350 group) and to investigate the
association of this pattern with alterations in the phenotypic
distribution of CD8 subsets. The 350 cells/ml-endpoint was chosen
based on the national and international recommendations for
HAART initiation by the year 2010, when most of these
individuals were already enrolled [22]. PHI,350 showed signif-
icantly higher VLs and lower CD4+ T-cell counts, both at baseline
(p = 0.0321 and p,0.0001 respectively) and set-point (p = 0.0466
and p = 0.0008, respectively), compared to the PHI.350 group
(Table 1).
Distribution of memory T-cell phenotypes in total and
HIV-specific CD8+ T-cells identified during primary HIV
infection as well as viremic and aviremic chronic
infections
In a previous study, we showed that CD8+ T-cell specificity and
function were related to control of early disease progression [20].
Based on that analysis, now we aimed to investigate the
distribution of memory phenotypes in both total and HIV-specific
CD8+ T-cell compartments during primary HIV infection (using
samples from 24 PHI subjects obtained at baseline, Table S1) and
its association with subsequent disease progression. Also, these
parameters were screened in 10 HDs, 10 Chronics and 11 ECs for
comparison purposes. For this, we performed a phenotypic
analysis of CD8+ T-cells by flow cytometry, which allowed
us to define four CD8+ T-cell sub-populations (Figure 1A):
naı¨ve (TNaı¨ve, CCR7
+CD45RO2), central memory (TCM,
CCR7+CD45RO+), effector memory (TEM, CCR7
2CD45RO+)
and terminal effector (TTE, CCR7
2CD45RO2) cells. The
distribution of these subsets was analyzed both in bulk and HIV-
specific CD8+ T-cells. The latter was identified as cells able to
degranulate (mobilize CD107A/B) and/or express cytokines (IFN-
c, IL-2 and/or TNF-a) upon stimulation with peptide pools
corresponding to Nef, p24, p17 or p2p7p1p6 proteins. All these
molecules (CD107A/B, IFN-c, IL-2 and TNF-a) were identified
using antibodies stained with the same fluorochrome (FITC) in
order to detect all cells responsive to stimulation, regardless of their
specific functionality. Figure S1 illustrates the gating strategy used.
i. Distribution of memory subsets within bulk CD8+ T-
cell is abnormal in viremic Chronics but does not
significantly distinguish PHI subjects, ECs or HDs. The
distribution of memory phenotypes within the total CD8+ T-cell
compartment showed the following hierarchy in all groups of
subjects analyzed: TTE.TNaı¨ve.TEM.TCM (Figure 1B). Al-
though this hierarchy was conserved in all groups, differences in
the proportion of the various sub-populations among groups were
observed. The highest median proportion of total CD8+ TNaı¨ve
cells (as defined for the purposes of this work) was found in ECs
(36.9%; IQ25–75: 24.2–44.2), followed by HDs (31.9%; IQ25–75:
11.0–38.8), PHI subjects (29.0%; IQ25–75: 15.4–38.9) and
Chronics (20.9%; IQ25–75: 17.4–26.6). The difference was not
statistically significant between ECs and HDs, it barely reached
statistical significance between ECs and PHI subjects (p = 0.0493)
and differed significantly in ECs versus Chronics (p = 0.0018). This
is in line with a previous report that indicates that naı¨ve T-cells still
comprise a large proportion of the T-cell compartment at early
times post-infection [19]. On the other hand, the highest
proportion of total CD8+ TTE cells was observed in Chronics
(66.5%; IQ25–75: 56.4–68.7), followed by PHI subjects (64.2%;
IQ25–75: 55.3–79.5), HDs (62.6%; IQ25–75: 51.9–71.8) and ECs
(56.8%; IQ25–75: 47.9–74.9) (Figure 1B). The median proportion
of total CD8+ TCM cells was statistically lower in PHI subjects
(0.6%; IQ25–75: 0.2–1.3) compared both to Chronics (1.3%;
IQ25–75: 0.6–2.8; p = 0.0127) and ECs (1.5%; IQ25–75: 0.3–3.3;
p = 0.0405). Finally, it was observed that Chronics had a
statistically higher proportion (<2-fold) of total CD8+ TEM cells
(13.9%; IQ25–75: 11.3–19.5), compared to ECs (7.1%; IQ25–75:
3.2–13.0; p = 0.0048), HDs (6.5%; IQ25–75: 3.2–11.2; p = 0.0076)
and PHI subjects (4.5%; IQ25–75: 2.5–10.1; p,0.0001). When a
similar analysis was performed within PHI subgroups (PHI.350
versus PHI,350) no statistically significant difference was
observed. Overall, these results indicate that the distribution of
memory phenotypes within the total CD8+ T-cell compartment
evaluated at early time-points post-infection is similar to that of
CD8+ T-Cell Phenotype in Primary HIV Infection
PLOS ONE | www.plosone.org 5 August 2014 | Volume 9 | Issue 8 | e104235
HDs and ECs. In contrast, a higher proportion of the most
differentiated TEM and TTE cells was found in viremic Chronics
while a higher proportion of the less differentiated TNaı¨ve and TCM
cells (similar to the scenario observed in HDs) was found in
aviremic chronically-infected subjects (i.e. ECs) (Figure 1B).
ii. HIV-specific CD8+ T-cells from recently infected
subjects preserve a maturation hierarchy similar to that
of ECs, whereas it is skewed in chronically viremic infected
subjects. The distribution of memory phenotypes within the
HIV-specific CD8+ T-cell compartment mostly mirrored that of
the total compartment. However, important differences were also
observed. It is worth noting here that, due to technical constraints,
our definition of naı¨ve T-cells is not strict enough to completely
avoid inclusion of very early differentiated memory cells such as
the so called stem-cell memory T-cells. To completely avoid
this problem, additional surface markers should be included
in the panel [31]. Hence, when referring to HIV-specific
CCR7+CD45RO2 CD8+ T-cells, we used the term ‘‘naı¨ve-like’’
(Tnaı¨ve-like).
The highest proportion of HIV-specific CD8+ Tnaı¨ve-like cells
was observed in ECs (24.2%; IQ25–75: 18.4–32.5) followed by
PHI subjects (18.5%; IQ25–75: 14.0–33.3) and Chronics (14.34%;
IQ25–75: 8.0–21.4; p = 0.0164) (Figure 1C). Chronics had a
significantly higher proportion of HIV-specific CD8+ TEM cells
(22.5%; IQ25–75: 10.0–28.2), compared to PHI subjects (7.4%;
IQ25–75: 4.6–18.3; p = 0.002) and ECs (8.8%; IQ25–75: 4.7–
15.8; p = 0.0111) and tended to have a lower proportion of HIV-
specific CD8+ TTE cells (54.9%; IQ25–75: 39.7–66.0) than PHI
subjects (58.9%; IQ25–75: 51.3–72.9) and ECs (63.5%; IQ25–75:
41.9–69.8). This is in line with previous studies which indicate
that, during chronic progressive HIV infection, there is a
maturation arrest of HIV-specific CD8+ T-cells from TEM to
TTE [6,32]. To provide further insights into this notion, the HIV-
specific TEM/(TEM+TTE) ratio was analyzed in all groups in order
to picture the proportion of TEM cells out of the total of the most
differentiated subsets from our panel (TEM plus TTE). In
consonance with the hypothesis mentioned above, the TEM/
(TEM+TTE) ratio was significantly higher in Chronics compared to
ECs (p = 0.0144) and PHI (p = 0.0042) (Figure 2A). No statistically
significant difference was observed between ECs and PHIs or
within PHI subgroups (PHI.350 versus PHI,350). Moreover,
the percentages of HIV-specific CD8+ TEM and TTE cells
negatively correlated in PHI subjects (r =20.458; p = 0.0095;
Figure 2B) and ECs (r =20.546; p = 0.0351; Figure 2C) whereas
no correlation at all was observed in Chronics (r = 0.258; p.0.05;
Figure 2D). These results support the notion that differentiation of
TTE cells from TEM cells is altered in viremic chronic HIV-1
infection. However, it might not be the case in ECs or, more
importantly, in recently infected subjects (PHI group) where these
results indicate that there exists an early preservation of the CD8+
T-cell compartment before going into the chronic stage of
infection.
Finally, based on previous results indicating that Gag-specific
CD8+ T-cells improved antiviral functions [20], it was hypothe-
sized that the distribution of memory phenotypes within the HIV-
specific CD8+ compartment would vary according to the antigens
used as stimulus; i.e. Nef versus Gag (p24, p17 or RG) peptide
pools. However, no clear association was found between antigen
specificity and CD8+ T-cell memory/effector phenotype in either
group analyzed (data not shown).
Baseline higher proportions of total and HIV-specific
CD8+ TEM cells as well as higher HIV-specific TEM/(TEM+
TTE) ratio correlated with markers of faster progression
while higher proportions of Tnaive and Tnaive-like CD8
+ T-
cells associated with markers of slower disease
progression
According to the data described above on the distribution of
memory phenotypes within both total and HIV-specific CD8+ T-
cell compartment in groups with differential disease outcome,
together with data collected from the bibliography, it was
hypothesized that within the PHI group, the relative frequency
of the different memory subsets evaluated at baseline would be
associated with disease progression. Thus, the relative frequency of
a given subset measured at early time-points post-infection could
be postulated as an indicator of subsequent disease progression
rate. To test this, correlation analyses were performed between the
percentages of the different memory subsets and the clinical data
of the subjects enrolled, obtained at baseline and during the first
year post-infection.
As regards the total CD8+ T-cell compartment, and always
within the PHI group, the proportion of TEM cells correlated
inversely with baseline CD4+ T-cell count (r =20.363; p = 0.0274;
Figure 3A) and directly with baseline activation levels within the
Table 2. Immune Activation Panel corresponding to HIV+ subjects enrolled per study groupa,b.
Median % (IQ)
Group (No.
of subjects) CD4/CD38 CD4/HLA-DR CD4/CD38/HLA-DR CD8/CD38 CD8/HLA-DR CD8/CD38/HLA-DR
PHI
All (n = 32) 21.7 (13.8–35.1) 5.0 (1.5.–8.4) 1.4 (0.4–2.2) 44.3 (22.5–55.7) 32.4 (15.5–44.8) 15.8 (7.4–34.7)
PHI .350
(n = 20)
23.1 (13.8–33.4) 6.7 (1.5–6.4) 1.2 (0.4–2.1) 33.7 (21.3–48.5) 24.9 (11.8–39.7) 9.7 (6.0–27.8)
PHI ,350
(n = 12)
18.3 (11.9–36.3) 8.2 (1.4–12.6) 1.5 (0.5–5.6) 48.2 (39.0–64.1) 40.2 (27.9–57.8) 33.4 (14.8–43.6)
Chronic
(n =10)
41.3 (28.1–46.1) 12.0 (5.2–18.5) 2.7 (1.1–18.5) 35.9 (24.4–91.7) 19.0 (18.2–49.8) 11.2 (5.6–24.4)
EC (n=11) 22.6 (12.9–32.9) 4.7 (2.3–9.1) 0.6 (0.4–1.7) 33.5 (28.2–44.5) 17.2 (12.3–31.9) 8.2 (3.2–12.8)
aFlow cytometry double platform, FACSCanto, BD Biosciences.
bFor PHI subjects, data correspond to baseline samples. For chronic and elite controller subjects, data correspond to samples obtained at enrollment.
IQ: Interquartile range.
doi:10.1371/journal.pone.0104235.t002
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CD8+ T-cell compartment (r = 0.349; p = 0.0368; Figure 3C).
Moreover, the proportion of TEM cells also correlated negatively
with the CD4+ T-cell count set-point (r =20.443; p = 0.0142;
Figure 3B) indicating that the early proportion of this subset is
associated with the subsequent level of immune set-point. When
analyzing the HIV-specific CD8+ T-cells compartment it was
found that the proportion of HIV-specific TEM cells inversely
correlated with baseline CD4+ T-cells (r =20.448; p = 0.0167,
Figure 3D) and the CD4+ T-cell count set-point (r =20.599;
p = 0.0086, Figure 3E). The same significant trends were observed
when the HIV-specific TEM/(TEM+TTE) ratio was measured
(r =20.472; p = 0.0129, Figure 3G; r =20.629; p = 0.0091,
Figure 3H, respectively). Additionally, the proportion of HIV-
specific TEM cells directly correlated with viral set-point (r = 0.571;
p = 0.0208, see Figure S3F). Then, the CD8+ T-cell activation was
analyzed. Direct correlations both with the percentage of HIV-
specific TEM cells (r = 0.489; p = 0.0132, Figure 3F), and with the
HIV-specific TEM/(TEM+TTE) ratio (r = 0.482; p = 0.0146, Fig-
ure 3I) were found. Furthermore, the HIV-specific TEM/(TEM+
TTE) ratio was also found to directly correlate with baseline plasma
levels of cytokines associated with disease progression such as IP-
10 (r = 0.499; p = 0.0251), IL-1a (r = 0.509; p = 0.0220), and IL-15
(r = 0.538; p = 0.0144, not shown). On the other hand, the
proportion of bulk CD8+ TNaı¨ve cells correlated directly with
baseline CD4+ T-cell count (r = 0.330; p = 0.0432, Figure S3A)
and inversely with baseline CD4+ T-cell activation (r =20.542;
p = 0.0008; Figure S3B). Similarly, the proportion of Tnaı¨ve-like cells
directly correlated with the percentage of baseline CD4+ T-cells
(r = 0.383; p = 0.0368, Figure S3C) while it inversely correlated
with baseline VL (r =20.460; p = 0.0093, Figure S3D) and viral
set-point (r =20.630; p = 0.0022, Figure S3E).
Overall, in line with the inter-group analysis performed above,
these results indicate that a higher relative proportion of both total
and HIV-specific CD8+ TNaı¨ve (or Tnaı¨ve-like) cells during early
time-points post-infection correlated with better immune status in
terms of CD4+ T-cell count, at baseline and set-point. Conversely,
higher proportions of the more differentiated TEM and its
accumulation relative to terminally differentiated cells within the
HIV-specific compartment (evaluated as the HIV-specific TEM/
(TEM+TTE) ratio) correlated with markers of faster disease
progression: lower baseline and set-point CD4+ T-cell counts,
higher viral set-point (only for the HIV-specific subset), and higher
baseline levels of cellular and soluble markers of immune
activation.
PD-1 expression on CD8+ T-cells during PHI is related to
disease progression and also with memory CD8+ T-cell
differentiation
In order to provide more insights into the phenotype of CD8+
T-cells found in HIV infection, the expression of Programmed cell
death 1 (PD-1), a molecule commonly linked to immune
exhaustion, was evaluated on bulk and HIV-specific CD8+ T-
Figure 2. Arrest of HIV-specific CD8+ T-cells from effector memory (TEM) to terminal effector (TTE) of subjects enrolled. HIV-specific
TEM/(TEM+TTE) ratio (A) of subjects enrolled per study group. Correlation among HIV-specific CD8+ TTE and the TEM cells in primary HIV infection (PHI)
(B), elite controllers (EC) (C) and Chronic (D) groups. PHI group N = 24 subjects (31 specific responses); EC N = 11 subjects (16 specific responses);
Chronics N = 10 subjects (13 specific responses). Panels A and B, open and filled green dots denote PHI.350 and PHI,350 subjects, respectively.
Panel A, P values were calculated using Mann-Whitney test. Asterisks denote different P values: * P,0.05; ** P,0.005. Panels B–D, r and P values
correspond to Spearman’s test.
doi:10.1371/journal.pone.0104235.g002
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cells from a subset of 19 PHI subjects using samples obtained at
861 months post-infection (due to cell sample availability). The
relationship between PD-1 expression and markers of disease
progression as well as with the distribution of memory subsets were
studied in this group. First, it was observed that PHI,350 subjects
displayed higher proportions of both total and HIV-specific PD-1+
CD8+ T-cells, compared to PHI.350 (45.6% versus 28.8%,
p = 0.0709 and 40% versus 25%, p = 0.0109, respectively;
Figure 4A). Despite not reaching statistical significance, a clear
tendency was observed. This trend was also recorded when PD-1+
events were subdivided into PD-1low (Figure 4B) and PD-1high
(Figure 4C) phenotypes according to the intensity (on the basis of
mean fluorescence intensity) of PD-1 expression. Interestingly,
bulk and HIV-specific CD8+ T-cells only differed significantly
regarding the proportion of PD-1high cells (p = 0.0294, Figure 4C).
In this sense, strong positive correlations were observed between
bulk and HIV-specific compartments regarding the proportion of
total PD-1+ cells (r = 0.7008, p,0.0001) and PD-1low cells
(r = 0.7674, p,0.0001, not shown). However, no significant
correlation was found in PD-1high cells (r = 0.3308, p = 0.07, not
shown). This indicates that PD-1 is preferentially up-regulated in
HIV-specific cells as described elsewhere [33–35]. Also, regarding
specific cells, no PD-1 expression difference was observed in cells
with different specificities (i.e. when Nef, Gag of CEF pools were
used as stimuli). According to the difference observed between
PHI.350 and PHI,350 subjects, negative correlations were
found between both bulk and HIV-specific PD-1+ CD8+ T-cells
and CD4+ T-cell percentages (r =20.510, p = 0.0109 and r =
Figure 3. Correlations between the proportion of CD8+ TEM cells within bulk (A–C) and HIV-specific (D–F) compartments as well as
the HIV-specific CD8+ TEM/(TEM+TTE) ratio (G–I) with clinical parameters measured in baseline samples from primary HIV infected
(PHI) subjects. Baseline CD4 T-cell counts (A), immune set point (B) and baseline immune activation (C) versus proportion of bulk CD8+ effector
memory (TEM) cells. Percentage of baseline CD4 T-cell (D), immune set point (E) and baseline immune activation (F) versus proportion of HIV-specific
CD8+ TEM cells. Percentage of baseline CD4 T-cell (G), immune set point (H) and baseline immune activation (I) versus HIV-specific CD8
+ TEM/(TEM+TTE)
ratio. PHI group N = 24 subjects (39 responses analyzed for bulk compartment and 31 responses for the specific compartment). For set point
correlations N = 15 subjects. In all panels, open and filled green dots denote PHI.350 and PHI,350 subjects, respectively. All r and P values
correspond to Spearman’s test.
doi:10.1371/journal.pone.0104235.g003
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20.457, p = 0.0216, respectively, Figures 4D and 4E). Otherwise,
no other association between PD-1 expression (measured as %PD-
1 or PD-1 MFI) on CD8+ T-cells (either total or HIV-specific) and
markers of disease progression (viral load, viral set-point, soluble or
cellular immune activation markers) was found. Alternatively,
when analyzing the proportion of PD-1low and PD-1high pheno-
types, a direct correlation between PD-1high CD8+ T-cells and
viral load was found (r = 0.447, p = 0.0287, Figure 4F).
Then, we sought to investigate the relationship between the
pattern of PD-1 expression and the distribution of memory subsets
during primary HIV infection. It was found that the percentages of
PD-1high CD8+ T-cells, both within bulk and HIV-specific
compartments, negatively correlated with the proportion of bulk
and HIV-specific CD8+ TEM cells (r =20.501, p = 0.0341 and
r =20.668, p = 0.0047, respectively; Figures 4G and 4I). Con-
versely, positive correlations were observed with the proportion of
bulk and HIV-specific CD8+ TTE cells (r =20.510, p = 0.0308
and r =20.564, p = 0.0228, respectively; Figures 4H and 4J).
Additionally, HIV-specific TEM/(TEM+TTE) ratio also correlated
inversely with the proportion of PD-1high CD8+ T-cells (r =
20.674, p = 0.0042; Figure 4K). This is in consonance with the
notion that PD-1 is not only a marker of immune cell exhaustion
but also its expression is related to CD8+ T-cell differentiation
stage and activation status [36].
CD8+ T-cell antiviral activity is related to CD8+ T-cell
memory differentiation but not to PD-1 expression
during primary HIV infection
We have previously shown that higher HIV-specific CD8+ T-
cell antiviral capacity during primary HIV infection was associated
with higher CD4+ T-cell counts at set-point [20]. Thus, we sought
to investigate the relationship between CD8+ T-cell phenotype
and functionality in a subset of 11 PHI subjects from our cohort.
This subset of 11 PHI subjects remained HAART-naı¨ve during
the study period. In the first place, no association was found
between the memory phenotype and the capacity of specific CD8+
T-cell to exert a particular function (degranulate or secrete
cytokines or chemokines) or with the proportion of polyfunctional
CD8+ T-cells. Additionally, no association was found among the
expression of PD-1 by CD8+ T-cells and its functionality.
Contrarily, significant inverse correlations were observed between
CD8+ T-cell antiviral activity (VIA) evaluated at baseline with the
concurrent proportion of HIV-specific CD8+ TEM cells (r =
20.593, p = 0.0096; Figure 5A) and the HIV-specific CD8+ TEM/
(TEM+TTE) ratio (r =20.613, p = 0.0069; Figure 5C). Conversely,
a positive correlation was obtained with the proportion of HIV-
specific CD8+ TTE cells (r = 0.718, p = 0.0008; Figure 5B). This
result indicates that the magnitude of CD8+ T-cell antiviral activity
during recent infection is related to a higher proportion of HIV-
specific cells with a fully differentiated phenotype, rapidly able to
exert effector functions. Concomitantly, a higher level of CD8+ T-
cell differentiation arrest (evidenced by higher TEM/(TEM+TTE)
ratios) translates into lower CD8+ T-cell antiviral activity.
Moreover, identical correlations were obtained when analyzing
CD8+ T-cell phenotype at baseline and antiviral activity at 12
months post-infection (Figure 5D to 5F) indicating that the early
CD8+ T-cell differentiation hierarchy is also associated with CD8+
T-cell antiviral function beyond the establishment of the set-point.
Discussion
Data accumulated over the last years have established that the
HIV-specific CD8+ T-cell response plays a critical role in viral
control (reviewed in [4,5,37]). For this reason, efforts have been
made to understand the properties of CD8+ T-cells (in terms of
function and/or phenotype) that best correlate with control of viral
replication [5]. Moreover, this information will be instrumental for
developing and enhancing immunization strategies focused on
eliciting appropriate immune responses as well as for defining
currently-lacking immune correlates of protection in order to
evaluate the performance of vaccine candidates. In line with this,
research studies on primary HIV infection (PHI) are increasing
worldwide to better understand the natural history of HIV
infection and to identify the early pathogenic events that may set
the course for subsequent disease progression. More specifically,
cohort studies addressing the association of particular features of
CD8+ T-cell responses arising during acute/early HIV infection
with potential markers associated with disease progression are
fundamental. However, most of these studies were performed in
developed countries, and scarce information exists from other
settings, such as South America, where local studies are needed to
comprehend particular characteristics of the infection. It is worth
highlighting that the capacity of cohort studies to provide
meaningful contributions relies on the definition of rigorous
inclusion criteria, which in turn allows for powerful comparisons of
both intra- and inter-studies. In this line, our group studied
multiple aspects of the HIV-specific CD8+ T-cell subset (specific-
ity, ex vivo viral inhibitory capacity and polyfunctionality) arising
early after infection, in a well-defined cohort of acute/early
infected subjects from Argentina, in comparison with that found
in, also local, viremic Chronics and ECs [20]. As an extension of
that preceding work, here we aimed at performing immunophe-
notypic analyses (in terms of memory markers and PD-1
expression) of the CD8+ T-cells, using the same cohorts of
subjects, in order to seek for associations with both CD8+ T-cell
functional properties and with viral control and subsequent disease
progression. Major findings indicate that i) the distribution of total
and HIV-specific CD8+ T-cell memory subsets is severely altered
in chronically infected subjects (excluding ECs). Although it is also
altered in recently infected subjects (PHI group), the shift is not so
profound as in Chronics (Figures 1 and 2); ii) within the PHI
group, higher proportions of Tnaive and Tnaive-like CD8
+ T-cells
associated with markers of slower disease progression while higher
proportions of total and HIV-specific CD8+ TEM cells as well as
higher HIV-specific TEM/(TEM+TTE) ratio correlated with
markers of faster progression (Figures 3 and S3); iii) analysis of
PD-1 expression on total and HIV-specific CD8+ T-cells from PHI
subjects revealed an association not only with disease progression
but also with memory CD8+ T-cell differentiation (Figure 4); and
iv) hierarchy of memory CD8+ T-cell subsets correlated with
CD8+ T-cell activity during primary HIV infection (Figure 5). Of
note, we consider that this study represents an important extension
beyond the scope of previous studies on CD8+ T-cell phenotype
during HIV infection, focused only on acute/early infection, ECs
or in comparing two opposite study populations (for instance, ECs
versus rapid progressors). Here, we simultaneously studied three
groups of HIV-infected subjects at different disease stages (acute
versus chronic) and with different clinical outcomes (controlled
versus non-controlled). Moreover, clinical follow-up of subjects
identified during primary infection allowed us to correlate the
CD8+ T-cell phenotype observed at baseline with subsequent
disease progression. In addition, we simultaneously studied cell
phenotype both in bulk and HIV-specific CD8+ T-cells, contrary
to other studies focused on the total compartment only. Finally, a
relationship between the distribution of CD8+ T-cell phenotypes
and CD8+ T-cell antiviral function could be established, a field in
which only a few reports exist (see below).
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So far, several groups have studied the distribution of memory
CD8+ subsets in HIV infection. The use of different markers and
the different numbers of such markers included in each study
make it a difficult task to compare and interpret inter-study results.
With some discrepancies, the general picture indicates that the
hallmark of HIV infection in terms of memory CD8+ T-cell
subsets consists in an accumulation of not fully differentiated cells.
This phenomenon was first described as a block toward terminal
Figure 4. The relationship between PD-1 expression and markers of disease progression as well as with the distribution of memory
subsets were studied in primary HIV infection (PHI) group. Percentage of PD-1 (A), PD-1Low (B), and PD-1High (C) cells out of bulk and HIV-
specific CD8+ T-cells, in samples from PHI subjects (N = 19; 30 specific responses) obtained at 8 months post-infection. (D to F) Correlations between
clinical parameters and percentage of PD-1 expression in the CD8+ T-cell subset, within the PHI group: Percentage of CD4 T-cells versus percentage of
bulk PD-1+ CD8+ T-cells (D) or PD-1+ HIV-specific CD8+ T-cells (E). Viral load versus percentage of PD-1High HIV-specific CD8+ T-cells (F). (G to K)
Correlation between baseline CD8+ T-cell memory subsets and percentage of PD-1 expression at 8 months post-infection (N = 11 subjects; 18 specific
responses): percentage of bulk CD8+ effector memory (TEM) (G) or terminal effector (TTE) (H) cells versus percentage of bulk PD-1
High CD8+ T-cells.
Percentage of HIV-specific CD8+ TEM (I), CD8
+ TTE (J) cells, or TEM/(TEM+TTE) ratio (K) versus percentage of PD-1High HIV-specific CD8+ T-cells. Panels A–C:
horizontal lines stand for median values. P values were calculated using Mann-Whitney test. Asterisks denote different P values: * P,0.05; ** P,0.005;
*** P,0.001. Panels D–K: r and P values correspond to Spearman’s test. In all panels, open and filled green dots denote PHI.350 and PHI,350
subjects, respectively.
doi:10.1371/journal.pone.0104235.g004
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differentiation within the HIV-specific compartment in progressive
chronic HIV infection [38] and subsequently confirmed even in
other settings such as acute infection [6,34,39]. Interestingly
enough, many studies have established a link between HIV-
specific memory CD8+ T-cell differentiation and disease progres-
sion [16,40,41]. Additionally, differentiation of total CD8+ T-cells
is also skewed in HIV infection and related to progression
[6,16,19,42,43]. In this context, our results reinforce the level of
knowledge into this field providing further support into these
notions. In the first place, and as reported elsewhere [16,19], our
results indicate that the distribution of memory subsets within bulk
CD8+ T-cell is abnormal in viremic Chronics but does not
significantly distinguish PHI subjects, ECs or HDs. Similarly, the
HIV-specific CD8+ T-cell compartment was only severely
compromised in Chronics but not in the PHI group. In this
scenario, early HAART initiation has been shown to provide not
only virological but also immunological benefits to HIV-infected
subjects. For instance, it was shown that the normal hierarchy in
CD8+ T-cell subset differentiation is not restored after HAART-
driven viral suppression [43–45] and that very early HAART
initiation limits the seeding of the HIV reservoir, particularly in
long-lived TCM cells [46,47]. Altogether, these data argue in favor
of early initiation of HAART, in order to prevent irreversible
deterioration of the mechanisms involved in immune homeostasis.
Further studies involving the relationship between immune
preservation (in terms of function and phenotype), size and
features of viral reservoir together with disease progression in a
PHI cohort are guaranteed.
Intriguingly, it was observed that the memory differentiation
hierarchy between the total and HIV-specific compartments did
not differ significantly in either group analyzed. This might reflect
that the force driving CD8+ T-cell differentiation in HIV infection
equally affects both compartments. Also, the memory differenti-
ation pattern did not differ between Gag-specific versus Nef-
specific responses, as previously reported [41,48]. Contrary to this,
Meyer-Olson et al. [39] described that epitope-specific CD8+ T-
cell maturation into memory/effector phenotypes is a TCR-
dependent process. The absence of difference in the specificities
observed in our study may be associated with the use of peptide
pools as stimuli which may mask such single-epitope differences.
As stated above, HIV infection is characterized by an
accumulation of preterminally differentiated (CD45RO+/
CCR72 or TEM as defined for the purposes of this work) HIV-
specific CD8+ T-cells and relative diminished frequency of fully
differentiated effector cells (CD45RO2/CCR72 or TTE). Our
inter-group analysis supports this notion since Chronics had a
significantly higher proportion of HIV-specific CD8+ TEM cells
than PHI subjects and ECs (p = 0.002 and p = 0.0111, respectevily)
and a trend to a lower proportion of HIV-specific CD8+ TTE.
Most important, Chronics had significantly higher HIV-specific
TEM/(TEM+TTE) ratios reflecting the accumulation of TEM over
TTE in Chronics but not in ECs (Chronics vs ECs p = 0.0144) or
PHI (Chronics vs PHI p = 0.0042). The same could be observed in
the correlation analysis of proportions of TEM versus TTE in all
groups of subjects: significant inverse correlations were obtained
for PHI (p = 0.0095) (as in [40]) and ECs (p = 0.0351) but not for
Chronics. Even more notably, the correlation analysis performed
within the PHI group indicated that the HIV-specific TEM/(TEM+
TTE) ratio evaluated at baseline inversely correlated with baseline
and set-point CD4+ T-cell levels and directly with cellular and
soluble markers of immune activation. This result, which adds
support to previously reported findings in other cohorts [16,40],
clearly indicate that the early deterioration of CD8+ T-cell
differentiation pathway associates with disease progression even at
Figure 5. Correlation between CD8+ T-cell capacity to suppress HIV replication ex vivo (VIA) and percentage of baseline HIV-specific
CD8+ T-cell subsets: CD8+ T-cell antiviral capacity measured at baseline versus percentage of HIV-specific CD8+ effector memory
(TEM) cells (A), CD8
+ terminal effector (TTE) cells (B), or CD8
+ TEM/(TEM+TTE) ratio (C). Antiviral CD8+ T-cell capacity measured at 12-months
post-infection versus percentage of baseline HIV-specific CD8+ TEM cells (D), CD8
+ TTE cells (E), or CD8
+ TEM/(TEM+TTE) ratio (F). N = 11 subjects (18
specific responses). In all panels, open and filled green dots denote PHI.350 and PHI,350 subjects, respectively. All r and P values correspond to
Spearman’s test. VIA: Viral inhibitory activity.
doi:10.1371/journal.pone.0104235.g005
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very early times post-infection. In this sense, our results, among
many other reports [16,44,49], have suggested a direct link
between maturation misbalance of the CD8+ T-cell memory
compartment and the generalized and persistent immune activa-
tion found in HIV+ subjects. However, which is the cause and
which the consequence is still not fully understood. A recent study
focused on ECs [50] suggested that, in these particular subjects,
maintenance of a less mature memory CD4+ T-cell population
provides the necessary T-cell help for optimal maturation of
effective CD8+ T-cell responses. In other words, the skewed
memory CD8+ T-cell phenotype might be the result of improper
CD4+ T-cell help. Alternatively, it was proposed that higher
proportions of TNaı¨ve cells in EC may reflect increased thymic
output in these subjects (compared to Chronics) which would
contribute to the replenishing of such compartment [51]. Similar
investigations in primary HIV infection are guaranteed to
elucidate the impact of memory CD4+ T-cell differentiation as
well as thymic function on the CD8+ T-cell subset in the context of
progressive HIV infection.
Expression of PD-1 on virus-specific CD8+ T-cells has been
consistently associated with a state of cellular exhaustion in the
context of persistent viral infections, with HIV infection not being
an exception [33,52–54]. However, data on acute HIV infection is
much more scarce [16,34,43,55]. Here, the expression of PD-1
was evaluated in bulk and HIV-specific CD8+ T-cells at 8 months
post-infection and related to clinical outcome as well as memory
CD8+ T-cell differentiation and functionality, aiming to provide a
broader picture of CD8+ T-cell phenotype hallmark in primary
HIV infection. In the first place, it was found that PD-1+ CD8+ T-
cells (both total and HIV-specific) were augmented in the PHI,
350 group, which had significantly lower CD4+ T-cell counts
compared to the PHI.350 group (p = 0.0341 and p = 0.0308,
respectively), suggesting a relationship of PD-1 expression with
faster disease progression. In line with this observation, inverse
correlations were obtained for PD-1+ CD8+ T-cells and CD4+ T-
cell counts. Similarly, other reports on primary HIV infection
[16,34] (and contrary to that described for chronic infection
[33,53]), found no associations between total PD-1 expression and
viral load. However, a relationship between the magnitude of
PD-1 expression and viral replication became evident when total
PD-1+ cells were split into PD-1Low and PD-1High cells: higher
proportions of PD-1High cells directly correlated with higher viral
load. This is consistent with the notion that PD-1 is up-regulated
on CD8+ T-cells due to T-cell activation in the presence of high
viral loads [36]. In this line, there is an increasing body of evidence
suggesting that PD-1 might be linked to T-cell exhaustion and
also, it would be a marker of cell activation [16,36] and a key
regulator of memory cell differentiation [35,43,56] and survival
[57]. Our results indicate that, at early times post-primary
infection (8 months post infection), higher proportions of PD-1high
CD8+ T-cells correlated with lower CD8+ TEM and higher CD8
+
TTE proportions. Likewise, other authors indicated that PD-1 is
expressed in all memory subsets, and that PD-1 up-regulation is
associated with cellular activation, with a reduction in proliferative
potential and with a higher sensitivity to cell death
[16,36,43,53,56,57]. Moreover, these results provide further
support to the revisited idea that, during acute infections, PD-1
is a cellular activation marker rather than an exhaustion marker as
it is in chronic infections [43,58]. Also in this context, several
reports have demonstrated that PD-1+ CD8+ T-cells can be fully
functional [34,58–60]. This is consistent with our failure in
identifying associations between PD-1 expression and HIV-specific
CD8+ T-cell functionality during primary HIV infection, as
Petrovas et al. [57] reported for chronic infection.
Contrary to what was obtained for PD-1 expression, significant
associations were found between memory CD8+ T-cell phenotype
and functionality. More precisely, lower and higher baseline
proportions of HIV-specific TEM and TTE CD8
+ T-cells,
respectively, correlated with higher ex vivo CD8+ T-cell antiviral
activity (VIA), both at baseline (p = 0.0096 and p = 0.0008,
respectively) and at 12 months post-infection (p = 0.0052 and p,
0.0001, respectively). Antiviral activity as evaluated in this work
encompasses both lytic and non-lytic antiviral mechanisms,
evidencing the overall capacity of HIV-specific cells to mediate
virus control. Previous reports have demonstrated, by isolating
pure populations of CD8+ T-cells (based on their memory
differentiation) from chronically HIV-infected subjects and vacci-
nees, that cells from all subsets could mediate VIA [15,61,62]. In
these reports, Elite Controller status [62] and control of
breakthrough infections in vaccinated monkeys [61] were associ-
ated with improved antiviral activity of the CD8+ TEM compart-
ment. In this line, here we were able to find a relationship between
the hierarchy of memory CD8+ T-cell differentiation and CD8+ T-
cell antiviral function in primary infection. Even when a priori
these results seem to be in contradiction, it must be noted that the
experimental approach and, most important, the setting are
completely different: we evaluated CD8+ T-cell antiviral function
in the context of high viral load and immune activation such as
acute/early infection meanwhile CD8+ T-cells from ECs and
vaccines are not subjected to such a hostile environment affecting
its functionality. This raises concerns over whether signatures of
CD8+ T-cell function or phenotype found in individuals such as
ECs are the cause or the consequence of virus control. Many
reports argue in favor of the latter hypothesis so caution should be
taken when interpreting such data. Conversely to VIA, no
association was found between memory CD8+ T-cell differentia-
tion and polyfunctionality. This is in contradiction with a report by
Riou et al. [41] showing that HIV-specific CD8+ T-cells show
decreasing polyfunctionality coinciding with an increase in
differentiation from early to terminally differentiated memory
subsets during HIV acute/early infection. Due to technical
constraints, these differences may be masked by our experimental
design.
Overall, here we report that normal maturation of total and
HIV-specific CD8+ T-cells into memory subsets is skewed in PHI
but not at the dramatic level observed in chronic infection.
Furthermore, the magnitude of this alteration in maturation
translates into a decrease in CD8+ T-cell antiviral capacity which
is directly correlated with early disease progression. Unscrambling
relationships among T-cell differentiation, T-cell functionality,
immune activation, viral control, and disease progression in
multiple settings (primary infection, viremic Chronics and ECs),
such as those observed in this work, are increasingly important to
advance our understanding of HIV pathogenesis. As well, this
information will be instrumental for therapeutic and sterilizing
vaccine design in order to boost our ability to elicit beneficial
responses.
Supporting Information
Figure S1 Gating strategy used for the identification of
different CD8 sub-populations, based on their pheno-
type, on bulk and HIV-specific T-cells. Illustration data
were derived from one representative subject, stimulated with an
HIV peptide pool. Initial gating was performed on a plot of
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forward scatter area (FSC-A) versus height (FSC-H) to remove
doublets. Then, gating was performed on small lymphocytes in a
plot of forward scatter (FSC) versus side scatter (SSC). Dead cells
were then excluded on the basis of LIVE/DEAD fluorescence.
Subsequently, CD3+ CD8+ cells were gated in a CD3-versus-CD8
dot plot. Following identification of these cells, HIV-specific CD8+
T-cells were identified in a CD8 versus. cytokines (FITC) density
plot. Then, the distribution of different phenotype subsets were
analyzed both in total and HIV-specific CD8+ T-cell compart-
ments. For this, CD45RO versus CCR7 density plots or PD-1
histograms (also PD-1Low or PD-1High) were performed on gated
CD3+CD8+ cells (bulk) or CD8+ Cytokines+ cells (HIV-specific).
Simultaneous use of CD45RO and CCR7 markers allowed us to
define four CD8+ T-cell sub-populations: naı¨ve (TNaı¨ve,
CCR7+CD45RO2), central memory (TCM, CCR7
+CD45RO+),
effector memory (TEM, CCR7
2CD45RO+) and terminal effector
(TTE, CCR7
2CD45RO2) cells.
(EPS)
Figure S2 Three groups of HIV infected subjects were
enrolled for this study: 32 subjects were recruited
during HIV seroconversion and/or within 6 months
since the presumed date of infection (PHI group), 10
chronically infected subjects (Chronics), and 11 subjects
defined as Elite Controllers (EC) according to the
criteria defined in materials and methods. Viral load (A)
CD4+ T-cell count (B) and Immune Activation (C) were
determined. Panels A and B, values corresponding to both
baseline and set point samples are shown for Primary HIV
infected (PHI) subjects. Viral and CD4+ T-cell set-points were
calculated as the geometric mean of determinations obtained
between 6 and 12 months post-presumed date of infection. Also,
subjects included in either PHI.350 and PHI,350 subgroups
(defined in materials and methods) are indicated by open and filled
green dots, respectively. Horizontal lines stand for median values.
P values were calculated using Mann-Whitney test. Asterisks
denote different P values: * P,0.05; ** P,0.005; *** P,0.001.
Within the PHI group, median baseline VL and CD4+ T-cell
counts were 34,800 RNA copies/ml (interquartile range (IQ)25–
75: 8,843–252,588 copies/ml) and 503 cells/ml (IQ25–75: 320–
682 cells/ml), respectively. As regards chronically infected subjects,
median VL was 28,435 RNA copies/ml (IQ25–75: 9,449–
197,984) and median CD4+ T-cell count was 141 cells/ml
(IQ25–75: 11–563) which was significantly lower than the other
groups (p = 0.016 and p = 0.0028 compared to PHI and ECs,
respectively). On the other hand, all ECs had undetectable plasma
VL (,50 RNA copies/ml) and the median CD4+ T-cell count was
602 cells/ml (IQ25–75: 562–888). PHI,350 showed, both at
baseline and set-point, significantly higher VLs (p = 0.0321 and
p,0.0001, respectively) and lower CD4+ T-cell counts (p = 0.0466
and p = 0.0008, respectively), compared to the PHI.350 group
and (see also Table 1).
(EPS)
Figure S3 Correlations between the proportion of the
different CD8+ T-cell subsets within bulk (A and B) and
the HIV-specific compartment (C to F) and clinical
parameters measured in baseline samples from prima-
ry HIV infected (PHI) subjects: Baseline CD4+ T-cell
counts (A) and baseline CD4 immune activation (B)
versus percentage of CD8+ TNaive cells. Percentage of HIV-
specific CD8+ TNaive-like cells versus percentage of baseline CD4
+
T-cell (C), baseline viral load (D) and viral set-point (E). (F)
Percentage of HIV-specific CD8+ TEM cells versus viral set-point.
PHI group N = 24 subjects (39 responses analyzed for bulk
compartment and 31 responses for the specific compartment). For
set point correlations N = 15 subjects. In all panels, open and filled
green dots denote PHI.350 and PHI,350 subjects, respectively.
All r and P values correspond to Spearman’s test.
(EPS)
Table S1 Characteristics of HIV+ subjects enrolled per study
group.
(DOCX)
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